Literature DB >> 15790929

Analysis of Gas6 in human platelets and plasma.

Istvan Balogh1, Sassan Hafizi, Jonas Stenhoff, Karin Hansson, Björn Dahlbäck.   

Abstract

OBJECTIVE: Gas6 is a member of the vitamin K-dependent protein family. Gas6-deficient mice were found to be resistant to thrombosis because of defective platelet function. Mouse Gas6 was demonstrated to be present in platelets and found to be involved in platelet aggregation. The aim of this study was to investigate the presence of Gas6 in human platelets and plasma and determine its role in platelet function. METHODS AND
RESULTS: The presence of Gas6 in human platelets and plasma was analyzed using sensitive immunologic methods. Mass spectrometry and ELISA were used to identify and quantify Gas6 in plasma. Gas6 was demonstrated to be present in human plasma, at a concentration determined to be 13 to 23 ng/mL (0.16 to 0.28 nM). Furthermore, plasma Gas6 levels were found to be lower in patients administered with warfarin. However, Gas6 was undetectable in human platelets.
CONCLUSIONS: This is the first report to identify and quantify Gas6 in human plasma. However, Gas6 protein was not detected in human platelets, suggesting that any potential platelet-specific function could be because of Gas6 from the circulation. These findings open up new directions regarding the role of Gas6 in normal and pathophysiological situations such as inflammation, autoimmune disease, thrombosis and arteriosclerosis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15790929     DOI: 10.1161/01.ATV.0000163845.07146.48

Source DB:  PubMed          Journal:  Arterioscler Thromb Vasc Biol        ISSN: 1079-5642            Impact factor:   8.311


  40 in total

1.  Elevated plasma gas6 levels are associated with venous thromboembolic disease.

Authors:  Mark D Blostein; Isabelle Rajotte; Deepa P Rao; Christina A Holcroft; Susan R Kahn
Journal:  J Thromb Thrombolysis       Date:  2011-10       Impact factor: 2.300

Review 2.  Minding the gaps to promote thrombus growth and stability.

Authors:  Lawrence F Brass; Li Zhu; Timothy J Stalker
Journal:  J Clin Invest       Date:  2005-12       Impact factor: 14.808

3.  Phenotypic screening identifies Axl kinase as a negative regulator of an alveolar epithelial cell phenotype.

Authors:  Naoya Fujino; Hiroshi Kubo; Rose A Maciewicz
Journal:  Lab Invest       Date:  2017-05-29       Impact factor: 5.662

4.  Serum growth arrest-specific protein 6 levels are elevated in adult-onset Still's disease.

Authors:  Hyoun-Ah Kim; Jin-Young Nam; Ju-Yang Jung; Chang-Bum Bae; Jeong-Mi An; Ja-Young Jeon; Bong-Sik Kim; Chang-Hee Suh
Journal:  Clin Rheumatol       Date:  2014-04-27       Impact factor: 2.980

Review 5.  Axl-dependent signalling: a clinical update.

Authors:  Vyacheslav A Korshunov
Journal:  Clin Sci (Lond)       Date:  2012-04       Impact factor: 6.124

6.  Plasma growth arrest-specific protein 6 levels in premenopausal and postmenopausal women: the role of endogenous estrogen.

Authors:  Yi-Jen Hung; Chien-Hsing Lee; Yi-Shing Shieh; Fone-Ching Hsiao; Fu-Huang Lin; Chang-Hsun Hsieh
Journal:  Endocrine       Date:  2014-03-28       Impact factor: 3.633

7.  TAM receptor ligands in lupus: protein S but not Gas6 levels reflect disease activity in systemic lupus erythematosus.

Authors:  Chang-Hee Suh; Brendan Hilliard; Sophia Li; Joan T Merrill; Philip L Cohen
Journal:  Arthritis Res Ther       Date:  2010-07-16       Impact factor: 5.156

Review 8.  Platelet receptors and signaling in the dynamics of thrombus formation.

Authors:  José Rivera; María Luisa Lozano; Leyre Navarro-Núñez; Vicente Vicente
Journal:  Haematologica       Date:  2009-03-13       Impact factor: 9.941

9.  GAS6/Mer axis regulates the homing and survival of the E2A/PBX1-positive B-cell precursor acute lymphoblastic leukemia in the bone marrow niche.

Authors:  Yusuke Shiozawa; Elisabeth A Pedersen; Russell S Taichman
Journal:  Exp Hematol       Date:  2009-11-14       Impact factor: 3.084

10.  Serum growth arrest-specific protein 6 levels are a reliable biomarker of disease activity in systemic lupus erythematosus.

Authors:  Hyoun-Ah Kim; Jin-Young Nam; Ja-Young Jeon; Jeong-Mi An; Ju-Yang Jung; Chang-Bum Bae; Chang-Hee Suh
Journal:  J Clin Immunol       Date:  2012-08-23       Impact factor: 8.317

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.